Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barré syndrome-like acute axonal neuropathies: report of two cases

Santiago-Casas, Yesenia; Peredo-Wende, Ruben; Vilá, LM

doi:10.1177/0961203313476358

Cited by 28 publications

(27 citation statements)

References 18 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ВВИГ назначается только в тяжелых и/или рези-стентных случаях СКВ. Лишь несколько авторов отметили положительный эффект ВВИГ у больных СКВ и ассоцииро-ванным синдромом Гийена-Барре [26], лечение должно быть начато не позднее чем через 3 мес с момента появле-ния симптомов. При воспалительной полиневропатии и синдроме Гийена-Барре рекомендации справедливы неза-висимо от их этиологии, специальных рандомизированных плацебоконтролируемых исследований (РПКИ) эффектив-ности ВВИГ при соответствующих СКВ-ассоциированных симптомах не проводилось [7].…”

Section: п о к а з а н и я д л я н а з н а ч е н и я в в и г в р е в unclassified

The place of intravenous immunoglobulin in rheumatic diseases

Середавкина¹,

Решетняк²,

Насонов³

2015

RJTAO

View full text Add to dashboard Cite

Section: п о к а з а н и я д л я н а з н а ч е н и я в в и г в р е в unclassified

The place of intravenous immunoglobulin in rheumatic diseases

Середавкина¹,

Решетняк²,

Насонов³

2015

RJTAO

View full text Add to dashboard Cite

“…GBS has been described as a presenting feature of SLE and a complication of established disease [137]. AIDP [138] and AMAN [137] appear most frequently, although FS [139] and BBE [140] have also been reported.…”

Section: Autoimmune Diseasesmentioning

confidence: 99%

“…AIDP [138] and AMAN [137] appear most frequently, although FS [139] and BBE [140] have also been reported. Other autoimmune diseases have also been implicated, including but not limited to: rheumatoid arthritis, inflammatory bowel disease, myasthenia gravis, Graves' disease [141] and Sjögren's syndrome [142].…”

Section: Autoimmune Diseasesmentioning

confidence: 99%

Infectious and noninfectious triggers in Guillain–Barré syndrome

Wakerley

Yuki

2013

Expert Review of Clinical Immunology

116

View full text Add to dashboard Cite

Guillain-Barré syndrome (GBS) is the commonest cause of acquired flaccid paralysis in the world and regarded by many as the prototype for postinfectious autoimmunity. Here the authors consider both infectious and noninfectious triggers of GBS and determine where possible what immunological mechanisms may account for this association. In approximately two-thirds of cases, an infectious trigger is reported in the weeks that lead up to disease onset, indicating that the host's response to infection must play an important role in disease pathogenesis. The most frequently identified bacteria, Campylobacter jejuni, through a process known as molecular mimicry, has been shown to induce cross-reactive anti-ganglioside antibodies, which can lead to the development of axonal-type GBS in some patients. Whether this paradigm can be extended to other infectious organisms or vaccines remains an important area of research and has public health implications. GBS has also been reported rarely in patients with underlying systemic diseases and immunocompromised states and although the exact mechanism is yet to be established, increased susceptibility to known infectious triggers should be considered most likely.

show abstract

“…There are reported cases of other acute neuropathies with or without antiganglioside antibodies including acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN), though it is unclear whether they are related to SLE. [89][90][91][92][93][94] Severe distal weakness is unusual.…”

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

Peripheral Neuropathies of Rheumatologic Disease and Gluten-Related Disorders

Reda

Chin

2014

Semin Neurol

View full text Add to dashboard Cite

Peripheral nervous system disease is a common and often debilitating feature of many systemic rheumatologic disorders. Such involvement takes many forms, reflecting the variety of underlying pathophysiology, though most patients present with painful multifocal neuropathy (usually vasculitic) or a distal sensory more than motor peripheral neuropathy (sometimes vasculitic and nearly always axonal). The presence of peripheral nervous system involvement is often an early signal of the generalization of inflammatory disease in blood vessels or extravascular tissues, though peripheral neuropathy is not itself an independent predictor of mortality. Nonetheless, progressive multifocal neuropathy, motor neuropathy, small fiber neuropathy, and sensory neuronopathy should be treated early and aggressively with immunosuppression (or the gluten-free diet in appropriate situations) to limit morbidity. Given the rapidly evolving therapeutic landscape, partnership with a rheumatologist is essential. Treatment is usually sustained for 1 to 2 years, and remission is possible in many cases within 6 to 12 months, with variable rates of relapse and treatment resistance. Patients should be meticulously monitored for relapse with serial laboratory testing, electrodiagnostic studies, and clinical examination. Functional rating scores, such as the neuropathy impairment scale and the total neuropathy score are useful for longitudinal assessment.

show abstract

Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barré syndrome-like acute axonal neuropathies: report of two cases

Cited by 28 publications

References 18 publications

The place of intravenous immunoglobulin in rheumatic diseases

The place of intravenous immunoglobulin in rheumatic diseases

Infectious and noninfectious triggers in Guillain–Barré syndrome

Peripheral Neuropathies of Rheumatologic Disease and Gluten-Related Disorders

Contact Info

Product

Resources

About